- Home
- PHT vs NGNE Comparison
PHT vs NGNE Comparison
Compare PHT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- NGNE
- Stock Information
- Founded
- PHT 2002
- NGNE 2003
- Country
- PHT United States
- NGNE United States
- Employees
- PHT N/A
- NGNE N/A
- Industry
- PHT Investment Managers
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- NGNE Health Care
- Exchange
- PHT Nasdaq
- NGNE Nasdaq
- Market Cap
- PHT 237.1M
- NGNE 251.9M
- IPO Year
- PHT N/A
- NGNE N/A
- Fundamental
- Price
- PHT $8.13
- NGNE $20.09
- Analyst Decision
- PHT
- NGNE Strong Buy
- Analyst Count
- PHT 0
- NGNE 7
- Target Price
- PHT N/A
- NGNE $41.86
- AVG Volume (30 Days)
- PHT 85.5K
- NGNE 240.1K
- Earning Date
- PHT 01-01-0001
- NGNE 08-08-2025
- Dividend Yield
- PHT 8.76%
- NGNE N/A
- EPS Growth
- PHT N/A
- NGNE N/A
- EPS
- PHT 0.98
- NGNE N/A
- Revenue
- PHT N/A
- NGNE $925,000.00
- Revenue This Year
- PHT N/A
- NGNE N/A
- Revenue Next Year
- PHT N/A
- NGNE N/A
- P/E Ratio
- PHT $7.71
- NGNE N/A
- Revenue Growth
- PHT N/A
- NGNE N/A
- 52 Week Low
- PHT $6.41
- NGNE $6.88
- 52 Week High
- PHT $7.60
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- PHT 68.89
- NGNE 57.57
- Support Level
- PHT $8.05
- NGNE $14.65
- Resistance Level
- PHT $8.05
- NGNE $18.21
- Average True Range (ATR)
- PHT 0.05
- NGNE 1.84
- MACD
- PHT -0.00
- NGNE 0.03
- Stochastic Oscillator
- PHT 90.48
- NGNE 80.24
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.